Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Proteasome inhibition with bortezomib is a validated approach to the treatment of multiple myeloma, but drug resistance often emerges and limits its utility in the retreatment setting. To begin to identify some of the mechanisms involved, we developed bortezomib-resistant myeloma cell lines that, un...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kuhn, Deborah J., Berkova, Zuzana, Jones, Richard J., Woessner, Richard, Bjorklund, Chad C., Ma, Wencai, Davis, R. Eric, Lin, Pei, Wang, Hua, Madden, Timothy L., Wei, Caimiao, Baladandayuthapani, Veerabhadran, Wang, Michael, Thomas, Sheeba K., Shah, Jatin J., Weber, Donna M., Orlowski, Robert Z.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2012
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3476538/
https://ncbi.nlm.nih.gov/pubmed/22932796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-10-386789
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky